174484-41-4
基本信息
N-[3-[(1R)-1-[(6R)-2-羟基-4-氧代-6-苯乙基-6-丙基-5H-吡喃-3-基]丙基]苯基]-5-(三氟甲基)吡啶-2-磺酰胺
Tipranavir
PNU-140690
Tipranavir(PNU-140690,Aptivus)
N-[3-[(1R)-1-[(6R)-2-Hydroxy-4-oxo-6-phenethyl-6-propyl-5H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
N-[3-[(1R)-1-[(6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
2-PyridinesulfonaMide,N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoroMethyl)-
物理化学性质
| 熔点 | 86-890C |
| 比旋光度 | D +20° (ethanol) |
| 沸点 | 712.3±70.0 °C(Predicted) |
| 密度 | 1.313±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C冷冻 |
| 溶解度 | 少许溶于甲醇 |
| 酸度系数(pKa) | 4.50±1.00(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至淡黄色 |
| BCS Class | 2 |
| InChIKey | SUJUHGSWHZTSEU-FYBSXPHGSA-N |
| SMILES | C1(S(NC2=CC=CC([C@H](C3=C(O)C[C@](CCC4=CC=CC=C4)(CCC)OC3=O)CC)=C2)(=O)=O)=NC=C(C(F)(F)F)C=C1 |
安全数据
| 危险性符号(GHS) |  GHS09 |
| 危险性描述 | H411 |
| WGK Germany | WGK 3 |
| 存储类别 | 11 - Combustible Solids |
| 毒害物质数据 | 174484-41-4(Hazardous Substances Data) |
常见问题列表
IC50: 66-410 nM (HIV-1 isolates)
Tipranavir (PNU-140690) inhibits the enzymatic activity of HIV-1 protease, blocks the dimerization of protease subunits, and exerts potent activity against a wide spectrum of wild-type and multi-PI-resistant HIV-1 variants. When a mixture of 11 multi-PI-resistant (but TPV-sensitive) clinical isolates (HIV 11MIX ), which include HIV B and HIV C , is selected against Tipranavir, HIV 11MIX rapidly (by 10 passages [HIV 11MIX P10 ]) acquires high-level Tipranavir (PNU-140690) resistance and replicates at high concentrations of Tipranavir (PNU-140690). cHIV B I54V and cHIV B I54V/V82T are significantly resistant to Tipranavir (PNU-140690), with IC 50 s of 2.9 and 3.2 μM, respectively, which are 11- and 12-fold increases in comparison to the IC 50 against cHIV B , respectively.
Tipranavir (PNU-140690) is administered orally twice daily and must be given in combination with low-dose ritonavir (RTV) to boost Tipranavir bioavailability. In Tipranavir/r-cotreated mice, the Tipranavir (PNU-140690) abundance in the liver, spleen, and eyes is significantly higher than that in mice treated with Tipranavir alone. Tipranavir (PNU-140690) metabolites accounts for 31 and 38% in the serum and liver in the Tipranavir-alone group. In Tipranavir (PNU-140690) and Tipranavir (TPV/r)-cotreated mice, only 1 and 2% of metabolites are detected in the serum and liver. Sprague-Dawley rats are administered a single dose of [ 14 C]Tipranavir (PNU-140690) with coadministration of RTV. The most abundant metabolite in feces is an oxidation metabolite. In urine, no single metabolite is found to be significantly present.
替拉那韦价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-15148 | 替拉那韦 Tipranavir | 174484-41-4 | 1mg | 950元 |
| 2026/09/15 | HY-15148R | 替拉那韦 Tipranavir (Standard) | 174484-41-4 | 1 mg | 3300元 |
| 2026/09/15 | HY-15148 | 替拉那韦 Tipranavir | 174484-41-4 | 5mg | 3300元 |